Kyntheum Uses, Dosage, Side Effects and more
Kyntheum has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Kyntheum was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Increase in the level of IL-17 due to blocking of its receptors.
| Trade Name | Kyntheum |
| Availability | Prescription only |
| Generic | Brodalumab |
| Brodalumab Other Names | Brodalumab |
| Related Drugs | Humira, Otezla, Cosentyx, methotrexate, Enbrel, Remicade, Stelara, cyclosporine, infliximab |
| Type | Injection |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Leo Laboratories Limited |
| Available Country | United Kingdom |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Kyntheum is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Kyntheum has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
Kyntheum is also used to associated treatment for these conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis
How Kyntheum works
Kyntheum binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.
Food Interaction
No interactions found.Disease Interaction
Major: Crohn's disease, depression, tuberculosis, vaccinationModerate: infections
Volume of Distribution
4.62 L.
Clearance
0.223 L/day.
